Key points are not available for this paper at this time.
To compare the safety of Janus kinase inhibitors (JAKi) with that of tumour necrosis factor inhibitors (TNFi) and determine drug persistence among patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA).
Hernández‐Cruz et al. (Tue,) studied this question.